V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320003256 | 320001965 | 1.65 | 50.4 | Neo-adjuvant (N) | 2015-05-17 | 2015-05-17 | null | 02 | N | 320019448 | BEVACIZUMAB |
| 320003257 | 320001966 | 1.76 | null | Palliative (P) | 2017-04-05 | 2017-04-13 | Cisplatin + Docetaxel +Fluorouracil | Y | N | 320019453 | CARBOPLATIN + ETOPOSIDE |
| 320003258 | 320001967 | 1.7 | null | Neo-adjuvant (N) | null | 2013-06-05 | FLUOROURACIL + MITOMYCIN + RT | null | null | 320019454 | NOT MATCHED |
| 320003259 | 320004977 | 1.59 | 53 | Curative (C) | 2016-05-12 | 2016-06-07 | BEVACIZUMAB + CARBO + PACLITAXEL | N | Y | 320019455 | MITOMYCIN INTRAVESICULAR |
| 320003260 | 320004977 | 1.6 | null | Curative (C) | 2015-08-07 | 2015-08-16 | HCX (Cape + Cisp + Tras) - Load | N | N | 320019455 | CARBOPLATIN + ETOPOSIDE |
| 320003261 | 320004977 | null | null | Adjuvant (A) | 2014-12-31 | 2015-01-27 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320019455 | POUT TRIAL |
| 320003262 | 320004977 | 1.56 | 57.8 | Palliative (P) | 2014-02-04 | 2014-03-03 | Capecitabine | N | N | 320019455 | PEMBROLIZUMAB |
| 320003263 | 320007356 | 1.72 | 67.7 | null | 2017-05-04 | 2017-05-05 | Cisplatin + Docetaxel +Fluorouracil | 2 | null | 320019478 | CARBO + FLUOROURACIL |
| 320003264 | 320001968 | 1.58 | 49.8 | Palliative (P) | 2017-08-21 | 2017-09-07 | VISMODEGIB | 2 | null | 320019513 | IPILIMUMAB + NIVOLUMAB |
| 320003265 | 320001969 | 1.76 | 78.5 | null | null | 2016-06-02 | Cisplatin + Etoposide (5 day) | null | null | 320019517 | CAPECITABINE + CISPLATIN |
| 320003266 | 320004978 | null | 78.5 | Adjuvant (A) | 2018-08-18 | 2018-08-18 | Everolimus 5mg | N | N | 320019518 | CISPLATIN + GEMCITABINE |
| 320003267 | 320001970 | 1.97 | 118.4 | Adjuvant (A) | 2015-03-29 | 2015-04-05 | CNS Low Grade Glioma Vinblastine | Y | Y | 320019524 | CARBOPLATIN + RT |
| 320003269 | 320001972 | null | 77.9 | Adjuvant (A) | 2015-05-15 | 2015-05-21 | Cetuximab + Radiotherapy Load | N | N | 320019541 | ICON TRIAL |
| 320003270 | 320001973 | 1.64 | 50.5 | Palliative (P) | 2013-09-19 | 2013-09-19 | Bortezomib + Cyclophos + Dex | Y | N | 320019543 | FEC + DOCETAXEL |
| 320003271 | 320001974 | 1.74 | 102 | Palliative (P) | 2017-06-04 | 2017-06-10 | EOF | 2 | N | 320019551 | CETUXIMAB + RT |
| 320003272 | 320001975 | 1.65 | 51.4 | Palliative (P) | 2016-07-27 | 2016-08-16 | POUT TRIAL | N | N | 320019555 | TRASTUZUMAB |
| 320003273 | 320001976 | 1.68 | null | Adjuvant (A) | 2016-06-30 | 2017-03-30 | CARBOPLATIN + RT | 02 | N | 320019567 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003274 | 320004979 | 1.68 | 71.6 | null | 2016-09-10 | 2016-10-05 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 320019571 | CARBO + FLUOROURACIL |
| 320003275 | 320001977 | null | 75.5 | Neo-adjuvant (N) | 2015-02-08 | 2015-02-23 | Carboplatin + Vinorelbine Oral | N | N | 320019582 | CISPLATIN + GEMCITABINE |
| 320003276 | 320001978 | null | 73 | Curative (C) | 2015-04-19 | 2015-05-10 | Carboplatin + Doxorubicin | 2 | N | 320019595 | PEMBROLIZUMAB |
| 320003277 | 320001979 | 1.76 | 58.5 | Curative (C) | 2013-05-30 | 2013-06-03 | Mitoxantrone | 2 | Y | 320019614 | CISPLATIN + GEMCITABINE |
| 320003278 | 320001980 | 1.8 | null | Palliative (P) | null | 2016-05-01 | Trial Unspecified | null | null | 320019621 | BCG |
| 320003279 | 320001981 | 1.91 | 9 | Adjuvant (A) | 2013-10-29 | 2013-11-22 | DE-ESCALATE TRIAL | N | N | 320019630 | CARBOPLATIN + RT |
| 320003280 | 320001982 | null | null | Not known (9) | 2013-11-12 | 2013-11-23 | Cetuximab + Radiotherapy Load | N | N | 320019633 | CETUXIMAB + RT |
| 320003281 | 320001982 | 1.7 | 89.4 | Curative (C) | 2013-11-09 | 2013-11-10 | BCG Intravesical | 01 | N | 320019633 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003282 | 320001983 | 1.59 | 86 | Adjuvant (A) | 2014-01-02 | 2014-01-05 | Enzalutamide | 1 | N | 320019647 | TEMOZOLOMIDE |
| 320003283 | 320001984 | 1.64 | 67.05 | null | 2014-05-18 | 2014-06-08 | FEC 100 | N | null | 320019652 | CARBO + LIPOSOMAL DOX + PACLITAXEL |
| 320003284 | 320004981 | 1.63 | 52.2 | Palliative (P) | 2016-04-16 | 2016-05-07 | ICON8 TRIAL | Y | N | 320019659 | CETUXIMAB + CISPLATIN + FU |
| 320003285 | 320004981 | 1.6 | 65 | Palliative (P) | 2016-04-22 | 2016-05-06 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 320019659 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN |
| 320003286 | 320001985 | 1.72 | 59.4 | Neo-adjuvant (N) | null | 2013-02-06 | Bevacizumab + Cape + Oxali 21day | N | N | 320019676 | DOXORUBICIN + IFOSFAMIDE |
| 320003287 | 320001986 | 1.47 | 56.65 | Curative (C) | 2014-06-12 | 2014-06-27 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320019677 | ICON8B TRIAL |
| 320003288 | 320001987 | 1.67 | 62.6 | Palliative (P) | 2014-03-11 | 2014-03-14 | Doxorubicin + Ifosfamide | 01 | N | 320019683 | TRIAL |
| 320003289 | 320001988 | null | 56.6 | 1 | 2015-05-03 | 2015-05-03 | Bevacizumab+Carbo+Gemcitabine | N | null | 320019686 | FEC + DOCETAXEL |
| 320003290 | 320001988 | 1.65 | 110 | Palliative (P) | null | 2015-12-22 | BCG Intravesical | null | null | 320019686 | CARBOPLATIN + RT |
| 320003291 | 320001988 | 1.71 | 88.1 | Curative (C) | 2013-05-05 | 2013-05-15 | Gemcitabine weekly | N | N | 320019686 | CISPLATIN + FLUOROURACIL + RT |
| 320003292 | 320001988 | 1.83 | 51.4 | Adjuvant (A) | 2014-10-02 | 2014-10-10 | Capecitabine 5days + RT | N | Y | 320019686 | NIVOLUMAB |
| 320003293 | 320001989 | 0 | 77.3 | Neo-adjuvant (N) | 2013-03-31 | 2013-04-07 | EW EuroEwing 99 : VIDE | N | N | 320019700 | CARBOPLATIN + RT |
| 320003294 | 320001990 | 1.82 | null | Neo-adjuvant (N) | null | 2015-03-14 | Carboplatin + Vinorelbine Oral | null | null | 320019705 | NOT MATCHED |
| 320003295 | 320001990 | 1.6 | 65.5 | Curative (C) | 2013-07-12 | 2013-08-09 | CISPLATIN + GEMCITABINE | N | Y | 320019705 | PEMBROLIZUMAB |
| 320003296 | 320001990 | 1.69 | 0 | Palliative (P) | 2015-04-20 | 2015-04-20 | Carboplatin + Pemetrexed | N | N | 320019705 | CISPLATIN + GEMCITABINE |
| 320003299 | 320001992 | 1.68 | null | Palliative (P) | 2015-03-19 | 2015-03-24 | Capecitabine (14 days)+Carboplatin | 01 | N | 320019743 | CETUXIMAB + CISPLATIN + FU |
| 320003300 | 320001992 | 1.86 | 67 | Palliative (P) | 2017-10-25 | 2017-11-08 | Tegafur | N | N | 320019743 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003301 | 320001993 | 1.6 | 69.199 | Curative (C) | 2017-10-23 | 2017-10-24 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | null | 320019750 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320003305 | 320006945 | 1.7 | null | Palliative (P) | 2017-01-30 | 2017-02-08 | Carboplatin + Etoposide iv&po | N | N | 320019847 | EOX |
| 320003306 | 320006945 | 1.7 | 77.9 | Adjuvant (A) | 2014-01-01 | 2014-01-05 | ICON8 TRIAL | 2 | N | 320019847 | EVEROLIMUS |
| 320003307 | 320006945 | 1.7 | 67.5 | Adjuvant (A) | 2017-08-21 | 2017-08-30 | BEVACIZUMAB + CARBO + PACLITAXEL | 2 | N | 320019847 | CETUXIMAB + RT |
| 320003308 | 320006945 | 1.67 | 55.4 | null | 2013-05-15 | 2013-05-23 | Temozolomide + RT | 02 | N | 320019847 | PEMBROLIZUMAB |
| 320003309 | 320001995 | null | 59.1 | Palliative (P) | 2013-12-22 | 2013-12-28 | Cisplatin + Vinorelbine (IV) | null | N | 320019889 | CAPECITABINE + OXALIPLATIN |
| 320003310 | 320001996 | 1.73 | 63.6 | Neo-adjuvant (N) | 2014-03-17 | 2014-03-24 | NIVOLUMAB | N | N | 320019897 | CARBO + FLUOROURACIL |
| 320003313 | 320004987 | 1.09 | null | Adjuvant (A) | 2015-04-01 | 2015-04-07 | OCTREOTIDE | N | N | 320019912 | IPILIMUMAB + NIVOLUMAB |